Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -6,13 +6,11 @@
6	6
7	7	* AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
8	8	* The company  focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
9		-* The company also has an active R&D presence in 40 other countries spanning the globe with 0,000 - employees work exclusively in R&D.
	9	+* The company also has an active R&D presence in 40 other countries spanning the globe with 10,000 - employees work exclusively in R&D.
10	10	* Commercial teams of around 43,400 employees are active in more than 100 countries
11	11
12		-
13	13	[[image:AZN0.png||height="175" width="721"]]
14	14
15		-
16	16	= Company Overview =
17	17
18	18	AstraZeneca (LSE:AZN, NASDAQ:AZN) is a global, science-led biopharmaceutical business and its innovative medicines are used by millions of patients worldwide.{{footnote}}https://www.astrazeneca.com/our-company.html{{/footnote}}
...	...	@@ -32,7 +32,6 @@
32	32	* 40 - active R&D presence in other countries spanning the globe
33	33	* 10,000 - employees work exclusively in R&D
34	34
35		-
36	36	The company's pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
37	37
38	38	* 175projects in its pipeline
...	...	@@ -39,7 +39,6 @@
39	39	* 17new molecular entities in its late-stage pipeline
40	40	* 1new molecular entity approval
41	41
42		-
43	43	[[image:AZN4.png||alt="AZN2.png"]]
44	44
45	45
...	...	@@ -86,7 +86,6 @@
86	86	* Building expertise and leadership in the most prevalent and highest mortality rate tumour types
87	87	* Delivering across its global footprint
88	88
89		-
90	90	**key disease areas**
91	91
92	92	The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients.
...	...	@@ -265,7 +265,6 @@
265	265	* Alexion integration progressing well, creating new opportunities in rare diseases
266	266	* Operating Expenses in the quarter reflected the addition of Alexion, as well increased R&D expenses across multiple programs, investment in its COVID-19 medicines, and increased SG&A from pre-launch activities following successful pipeline delivery
267	267
268		-
269	269	**Pascal Soriot, Chief Executive Officer, commented:**
270	270
271	271	AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery, with eight positive late-stage readouts across seven medicines since June, including its long acting antibody combination showing promise in both prevention and treatment of COVID-19. The addition of Alexion furthers its commitment to bring transformative therapies to patients around the world, and I am proud of its colleagues’ ongoing dedication and focus.
...	...	@@ -284,7 +284,6 @@
284	284	* In the US, Total Revenue increased by 29% to $8,305m and in Europe by 40% (31% at CER) to $5,178m, including pandemic COVID-19 vaccine revenue of $736m
285	285	* Growth in Core EPS13 to $5.05 to $5.40, in line with prior guidance.
286	286
287		-
288	288	Oncology Total Revenue of $9,744m in the year to date; an increase of 19% (16% at CER). Oncology represented 38% of overall Total Revenue (YTD 2020: 43%).
289	289
290	290